| Biomarker ID | 1042 |
| PMID | 23342084 |
| Year | 2013 |
| Biomarker | Early Growth Response 3 (Egr3) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa (5.35 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Inhibition of activated T cell apoptosis by neuropeptides VIP and PACAP, Regulation of NFAT transcription factors, Differentiation pathway in PC12 cells, Interleukin-5 regulation of apoptosis, BDNF signaling pathway |
| Experiment | Prostate Cancer Vs Normal Prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 84 patients with Prostate cancer and 13 with normal prostate were selected for the study. (GEO GSE17951 and GEO GSE8218) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p = 2 x 10^-15 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |